Efficacy and safety of trabectedin in patients with advanced or ...

Efficacy and Safety of Trabectedin in Patients With Advanced or ...

This trial documents superior disease control with the q3 weeks 24-hour trabectedin regimen in liposarcomas and leiomyosarcomas.

Efficacy and safety of trabectedin in patients with ... - PubMed

Prior studies showed clinical benefit with trabectedin in patients with sarcomas after failure of standard chemotherapy.

Efficacy and Safety of Trabectedin in Patients With Advanced or ...

Trabectedin may now be considered an important new option to control advanced sarcomas in patients after failure of available standard-of-care therapies.

Results of a Phase III Randomized Multicenter Clinical Trial - PubMed

Trabectedin demonstrates superior disease control versus conventional dacarbazine in patients who have advanced liposarcoma and ...

Efficacy and safety of trabectedin or dacarbazine for the treatment of ...

Toxicities were consistent with the well-characterized profiles of both treatments. Conclusions: Among patients with uterine LMS, treatment with trabectedin ...

Efficacy and safety of trabectedin or dacarbazine in patients with ...

In this post hoc subset analysis of patients with uLMS who had received prior anthracycline therapy, trabectedin treatment resulted in significantly longer PFS ...

Efficacy and safety of trabectedin in patients with advanced or ...

Although somewhat more neutropenia, elevations in AST/ALT, emesis, and fatigue occurred in the q3 weeks 24-hour trabectedin regimen, this regimen was ...

Efficacy and safety of trabectedin for patients with unresectable and ...

In Japan, a phase 1 pharmacokinetic study of trabectedin administered to patients with advanced STS resulted in a recommended dose of 1.2 mg/m2 ...

Efficacy and safety of trabectedin in an elderly patient subgroup ...

Background: Elderly patients (pts) (≥65 yrs) with soft tissue sarcoma may have limited treatment options due to increased comorbidities and toxicities from ...

Efficacy and safety of trabectedin or dacarbazine for metastatic ...

Conclusion: Trabectedin demonstrates superior disease control versus conventional dacarbazine in patients who have advanced liposarcoma and ...

Efficacy and safety of trabectedin in metastatic uterine leiomyosarcoma

More patients receiving trabectedin in 1st-line of advanced disease achieved CR (16.7%) and PR (50.0%) than those in ≥ 2nd line/s (0.0% and 20.0%), whereas the ...

Efficacy and safety of trabectedin in patients with advanced or ...

Febrile neutropenia was rare (0.8%). No cumulative toxicities were noted. Conclusion: Prior studies showed clinical benefit with trabectedin in ...

Real-World Experience of Efficacy and Safety of Trabectedin in ...

At locally advanced or metastatic stage, patients have less than 10% 5-year overall survival (OS). Systemic chemotherapy remains the standard ...

Assessment of Safety and Efficacy of Combined Trabectedin and ...

Our prospective trial resulted in an ORR of 72%, whereas the RECIST-based ORR with trabectedin alone in patients with advanced STS is below 10%.

Efficacy of Trabectedin in Patients with Advanced Translocation ...

Trabectedin is reported as effective, especially against translocation‐related sarcomas (TRSs) after failure of or intolerance to standard chemotherapy.

Clinical outcomes and safety with trabectedin therapy in patients ...

Two (1%) patients, each with leiomyosarcoma and liposarcoma, exhibited CR. A total of 258 patients with L-sarcoma experienced either CR, PR, or stable disease, ...

Safety and efficacy of trabectedin when administered in the inpatient ...

Of the 378 patients who were treated with trabectedin, 100 (27%) and 277 (73%), respectively, first received trabectedin in the inpatient and ...

A review of the Efficacy of Trabectedin as Second-Line Treatment of ...

Despite most patients (81%) in the best supportive care group crossing over to receive trabectedin after disease progression, median overall survival (OS) was ...

Trabectedin plus Durvalumab in Patients with Advanced Pretreated ...

This is the first full report of a study investigating the combination of trabectedin with an immune checkpoint inhibitor in solid tumors. In this study of ...

Safety and Efficacy in the Treatment of Advanced Sarcoma

Clinical benefit rates seem to favor its use especially in pretreated patients with recurrent/metastatic disease. The drug is well tolerated in general but ...